dronabinol 10 mg one capsule by mouth at 8:00 a.m.

includes groups randomized to receive placebo first or dronabinol 10 mg first

Entire Study Population

Sex: Female, Male

Region of Enrollment

electrophysiological measure of ability to filter extraneous stimuli measured as the amplitude of the evoked response to the second auditory stimulus divided by the amplitude of the evoked response to the first auditory stimulus in mV.

Dronabinol

Placebo

P50 Auditory Evoked Potential

ability to remember a list of words given 5 trials. Number of words remembered is normalized to a schizophrenia population and average scores are calculated with age correction. The normal T-score is 50 and scores greater than 50 correspond with greater ability to remember words as compared to a schizophrenia population norm.

California Verbal Learning Test Change at 2 Hours From Baseline

Measures psychiatric symptoms. Each item is scored from 1-7. Positive symptoms are calculated from sum of scores on hallucinatory behavior, unusual thought content and conceptual disorganization. Thus, the range of Total Positive Symptoms can be from a score of 3-21 .The higher the score, the more severe the symptom. Negative symptoms have been calculated from sum of blunted affect, emotional withdrawal and motor retardation. The range of Total Negative Symptoms can be from a score of 3-21. The higher the score, the more severe the symptoms. As this is a difference from baseline, there can be either negative or positive results as the subjects can either be better than baseline (positive score) or worse than baseline (negative score).

Brief Psychiatric Rating Scale Change From Baseline at 1 Hour

dronabinol 10 mg given oral one dose in first intervention period then 1 week washout period and then placebo given oral in one dose in second intervention period

Dronabinol 10 mg First Then Placebo

identical capsule given orally once in first intervention period then 1 week washout period then dronabinol 10 mg given orally once in second intervention period

Placebo First Then 10 mg Dronabinol

First Intervention

Washout

Second Intervention

Lynn Johnson, Pharm.D.

Schizophrenia

Placebo Comparator

University of Colorado Denver

The Effects of Cannabis Use in People With Schizophrenia on Clinical, Neuropsychological and Physiological Phenotypes

University of Colorado, Denver

National Alliance for Research on Schizophrenia and Depression

Cognitive-behavioral treatment program that integrates strategies to manage both cannabis use and anxiety with techniques to address motivation to change cannabis use.

Motivational Enhancement Therapy (MET) and cognitive-behavioral therapy (CBT) that includes techniques to address motivation to change cannabis use with strategies to manage use.

Cannabis Dependence

Anxiety Disorders

Cannabis Use Disorder

Cannabis Abuse

Cognitive-Behavioral Therapy

Motivation Enhancement Therapy

Integrated Cannabis and Anxiety Reduction Treatment

False Safety Behavior Elimination Therapy

Louisiana State University Anxiety & Addictive Behaviors Clinic

Integrated CBT for Cannabis Dependence With Co-occurring Anxiety Disorders

Julia Buckner

Associate Professor

Louisiana State University and A&M College

National Institute on Drug Abuse (NIDA)

Subjects will receive cannabis with placebo THC

Subjects will receive cannabis with 5.9% THC

Subjects will receive cannabis with 13.4% THC

Cannabis Intoxication

Participants will smoke a cannabis cigarette ad libitum as per their usual routine

cannabis

UC Center for Medicinal Cannabis Research

UC Center for Medicinal Cannabis Research, UC San Diego

Using a Field Performance Test on an iPad to Evaluate Driving Under the Influence of Cannabis

A Randomized, Controlled Trial of Cannabis in Healthy Volunteers Evaluating Simulated Driving, Field Performance Tests and Cannabinoid Levels

The GDDS is comprised of key variables from the simulator tasks (e.g., crashes, running a red light and perception response time for the amber light dilemma, SDLP, SuRT accuracy, time to collision on the gap acceptance task, failure on the audio direction task).

Driving simulation measuring standard deviation of lateral position (in feet) during the SuRT task

Participants will be instructed to maintain their speed during the SuRT task. The primary outcome is speed deviation in miles per hour.

Participants will be instructed to respond to divided attention stimuli in the SuRT task. The primary outcomes are number correct and response latency.

The outcome is coherence between the participant and lead cars (a general correlation [0-1] of the participant's ability to accurately track the speed variations of the lead car).

The outcome is time delay in seconds (response time to changes in the lead car's speed).

The outcome is distance (number of feet) from the lead car.

In order to assess treatment effects during routine and non-routine events the investigator will include scenarios addressing crash avoidance (e.g., object entering the roadway).

Stopping accuracy and perception response time will be measured after the traffic light turns yellow.

The time to collision with on-coming vehicles will be assessed.

The participant will follow a moving target (square) with her/his finger.

The research associate will administer a brief measure of time estimation with randomly generated durations.

To assess balance, participants will perform a Modified Romberg Test, without the time estimation component. Circular, forward-backward, and lateral postural sway will be assessed via an accelerometer.

Short term memory will be tested using a visual-spatial learning test.

It has been hypothesized that several cannabinoids (e.g., THC-glucuronide, cannabidiol and cannabinol) might be useful for estimating the last time of cannabis intake The outcome will be the concentration of each cannabinoid expressed in nanograms per milliliter.

The levels of cannabidiol in the oral fluid samples will be determined in nanograms per milliliter.

The levels of cannabinol in the oral fluid samples will be determined in nanograms per milliliter.

The levels of THC-glucuronide in the oral fluid samples will be determined in nanograms per milliliter.

false/cannabis

The Effects of Cannabis Use in People With Schizophrenia on Clinical, Neuropsychological and Physiological Phenotypes

Integrated CBT for Cannabis Dependence With Co-occurring Anxiety Disorders

Using a Field Performance Test on an iPad to Evaluate Driving Under the Influence of Cannabis

La base de datos de hierbas medicinales más completa respaldada por la ciencia